Back

Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials

28 August 2026 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Erik Stroes

AmsterdamUMC location AMC, Amsterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
Professor S. Zhong (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Doctor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III
Doctor P. C Revaiah (New York, US)
Abstract Slides Video
Presentation thumbnail
ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Professor S. Tsimikas (La Jolla, US)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials
28 August 2026
thumbnail
Congress Presentation
Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study
29 August 2026
thumbnail
Congress Session
Strategies to reach LDL-C goals in patients with high or very high CV risk: what's new for inclisiran?
27 August 2023
thumbnail
Congress Presentation
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources